Predictive Biomarkers Market Size, Share and Trends Analysis 2026 to 2035
Global Predictive Biomarkers Market Size is valued at USD 27.41 Bn in 2025 and is predicted to reach USD 156.51 Bn by the year 2035 at a 19.7% CAGR during the forecast period for 2026 to 2035
Predictive Biomarkers Market Size, Share & Trends Analysis Report By Indication (Cancer, Neurological Disorder, Cardiovascular Disorder, Immunological Disorder, Others), By End-Use (Diagnostic Centers, Contract Research Organizations (CROs), Academic Research Institutes, Pharma & Biotech Companies, Others), By Region, And By Segment Forecasts, 2026 to 2035

Predictive biomarkers are biological traits or molecular signals that can predict how a person might respond to a specific treatment or intervention. These biomarkers are used in a variety of sectors, such as medicine, pharmacology, and personalized healthcare, to forecast a patient's reaction to a given medication or to identify individuals who are more likely to benefit from a specific treatment.
The growing emphasis on personalized treatment and targeted medicines has been a major driving force in the predictive biomarkers market. The need for biomarker-based diagnostics and therapeutics has increased as healthcare practitioners strive to improve treatment outcomes while minimizing side effects. However, the pandemic hampered clinical trials in a variety of therapeutic fields, including those using predictive biomarkers. Many trials were halted, postponed, or adjusted to address safety concerns and alter healthcare priorities.
Competitive Landscape:
Some major key players in the Predictive Biomarkers Market:
- Thermo Fisher Scientific Inc.
- Qiagen N.V.
- Hoffmann-La Roche AG
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- Illumina Inc.
- Merck KGaA
- Bio-Techne Corporation
- Siemens Healthineers AG
- PerkinElmer, Inc.
- Myriad Genetics, Inc.
- Becton, Dickinson and Company
- Danaher Corporation
- Genomic Health, Inc.
- Pacific Biosciences of California, Inc.
- Others
Market Segmentation:
The Predictive Biomarkers Market is segmented on the basis of indication and end-use. As per the segment indication, the market is segmented as cancer, neurological disorder, cardiovascular disorder, immunological disorder, and others. The end-user segment includes diagnostic centers, Contract Research Organizations (CROs), academic research institutes, pharma & biotech companies, and others.
According To End-Use, The Diagnostic Centers' Segment Is Accounted As A Significant Contributor In The Predictive Biomarkers Market
The diagnostic centers' category is expected to hold a major share of the global Predictive Biomarkers Market in 2022. The increasing use of biomarkers in the detection of diseases such as cancer and others is a primary element driving the segment's revenue growth. The widespread availability of Deoxyribonucleic Acid (DNA) biomarker tests is helping to drive revenue growth in this market. Other important factors driving revenue growth in the market during the projected period include rapid technical breakthroughs and the use of technologies such as microarrays, next-generation sequencing techniques & mass spectrometry for nucleic acids.
The Cancer Segment Witnessed Growth At A Rapid Rate
The cancer segment is projected to grow at a rapid rate in the global Predictive Biomarkers Market. The rising incidence of cancer around the world is primarily responsible for the segment's growth. Cancer is the leading cause of death in every country and a substantial impediment to extending life expectancy. According to the American Cancer Society, there will be about 236,740 lung cancer patients in the United States by 2022. Additionally, increased demand for personalized medication is contributing to the segment's revenue growth.
In The Region, The North American Predictive Biomarkers Market Holds A Significant Revenue Share
The North American Predictive Biomarkers Market is expected to register the maximum market share in terms of revenue in the near future. Significant investments in healthcare infrastructure, as well as the quick use of biomarkers, are key drivers of market revenue development in this area. Rising cancer and other disease incidences are driving market revenue growth. Market enterprises operating in this region's various countries are establishing awareness programs connected to disease diagnosis and early screening, as well as the search for potential treatment solutions.

These activities have a substantial impact on market revenue growth. Moreover, Europe is expected to grow significantly in the coming years. Rapid technical improvements, as well as the presence of firms such as F. Hoffman-La Roche Ltd., Siemens Healthcare GmbH, and others, are driving market revenue growth in this region. Significant investments in R&D activities are helping the market's revenue growth in this region.
Predictive Biomarkers Market Report Scope :
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 27.41 Bn |
| Revenue Forecast In 2034 | USD 156.51 Bn |
| Growth Rate CAGR | CAGR of 19.7% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Indication, End-User |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Thermo Fisher Scientific Inc., Qiagen N.V., F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Illumina Inc., Merck KGaA, Bio-Techne Corporation, Siemens Healthineers AG, PerkinElmer Inc, Pacific Biosciences of California, Inc., Genomic Health, Inc., Danaher Corporation, Becton, Dickinson and Company, and Myriad Genetics, Inc |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Predictive Biomarkers Market :
Predictive Biomarkers Market, By Indication-
- Cancer
- Neurological Disorder
- Cardiovascular Disorder
- Immunological Disorder
- Others

Predictive Biomarkers Market, By End-Use-
- Diagnostic Centers
- Contract Research Organizations (CROs)
- Academic Research Institutes
- Pharma & Biotech Companies
- Others
Predictive Biomarkers Market, By Region-
- North America-
- The US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
- Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Predictive Biomarkers Market Size is valued at USD 27.41 Bn in 2025 and is predicted to reach USD 156.51 Bn by the year 2035
Predictive Biomarkers Market expected to grow at a 19.7% CAGR during the forecast period for 2026 to 2035
Thermo Fisher Scientific Inc., Qiagen N.V., F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Illumina Inc., Merck KGaA, Bio-Techne Corporation, Siemens Healthineers AG, PerkinElmer Inc, Pacific Biosciences of California, Inc., Genomic Health, Inc., Danaher Corporation, Becton, Dickinson and Company, and Myriad Genetics, Inc and Others.
Indication and End-User are the key segments of the Predictive Biomarkers Market.
North American region is leading the Predictive Biomarkers Market